Marginal Revolution: targeted cures create a financing dilemma

Marginal Revolution: targeted cures create a financing dilemma

In a post on Marginal Revolution, an unnamed speaker introduces the paper “The Price of a Cure: Luxturna and the Economic Dilemmas of Precision Medicine.” The post challenges the framing of Luxturna’s $850,000 price as private profiteering from publicly funded science. It argues that pharmaceuticals are a hit-driven industry: because most projects fail, successful drugs need to earn more than their direct costs to attract investment across the portfolio. For targeted cures, the post identifies two further pressures. A one-time payment for a cure compresses decades of value into one bill, making financing more of a problem than value. Targeting a drug to a smaller patient group also shrinks its market, which the post says can require higher rewards per patient to sustain incentives to innovate. The paper proposes amortizing payments over time, bundling diagnostics with drugs and insurance, and streamlining regulation to lower development costs. Its stated aim is to preserve innovation while expanding patient access. The post says more such drugs are expected, but gives no implementation details for its proposed toolkit.

Publication: 983320f9-f6a4-4eb9-8954-416af82c1e30

attribution — uncertain: The draft calls the writer an 'unnamed speaker' who 'introduces the paper,' but the post describes it as the author's own work. The evidence does not name the author, so the identity remains unclear. The reading also obscures that the poster is presenting their own argument, not reviewing someone else's. Smallest repair: say the post's unnamed author presents their own paper, published in the Journal of Law, Medicine and Ethics.

My latest paper, The Price of a Cure: Luxturna and the Economic Dilemmas of Precision Medicine, is in the Journal of Law, Medicine and Ethics.

summary — uncertain: The argument is faithfully conveyed, but the central term Luxturna is never identified as a gene therapy. Precision medicine and targeted drugs also go unexplained, so a general reader may not know what is being priced. The title merges two distinct challenges into a 'financing dilemma'; the source labels only the sticker-shock issue as a financing problem. The question is reasonable. Smallest repair: identify Luxturna as a gene therapy and briefly explain precision medicine as drugs aimed at narrow patient groups.

The $850,000 price for the gene therapy Luxturna is often framed as a story of private profiteering from publicly funded science.

date — pass: originalPublished (2026-11-02T12:16:34Z, publisher page) matches the feed entry and is consistent with first observation shortly afterward. No earlier publication is indicated.

support — pass: Each claim closely tracks the source's wording and is framed as the post's or paper's argument. Hedging such as 'can require' slightly softens 'requiring' but does not misrepresent it. The limitation about missing implementation details accurately reflects the post. No unsupported benefits or costs are introduced.

Rather than simply controlling prices, the paper proposes a policy toolkit that includes amortizing payments over time, bundling diagnostics with drugs and insurance, and streamlining regulation to lower development costs.

media — pass: The selected media is the verified direct link to the original Marginal Revolution post, which is the source itself.